| abstract |
In one aspect, the present invention relates to compounds of formula AA, or a pharmaceutically acceptable salt thereof. The variables represented in the formula AA are as defined in the claims. Compounds of formula AA are modulators of NLRP3 activity and are therefore suitable for use in the treatment of metabolic disorders (e.g., Type 2 diabetes, atherosclerosis, obesity or gout), a central nervous system (eg, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis or Parkinson's disease), lung disease (eg, asthma, COPD or idiopathic pulmonary fibrosis), liver (eg, NASH syndrome, viral hepatitis or cirrhosis), pancreas disease (eg acute pancreatitis or chronic pancreatitis), kidney disease (eg, acute kidney injury or chronic kidney injury) , an intestinal disease (eg Crohn's disease or ulcerative colitis), skin disease (eg psoriasis), musculoskeletal disease (eg, scleroderma), bucket (for example, giant cell arteritis), bone disorders (eg osteoarthritis, osteoporosis or osteopetrosis), eye disease (eg, glaucoma or macular degeneration), disease caused by a viral infection (eg HIV or AIDS), an autoimmune disease (eg rheumatoid arthritis, systemic lupus erythematosus or autoimmune thyroiditis), cancer or aging. |